The Radiation Therapy Oncology Group (RTOG) 0617 study¹ was an intergroup phase 3 trial that randomized patients with unresectable stage III non–small-cell lung cancer (NSCLC) to 1 of 4 treatment arms in a 2 × 2 factorial design: 60-Gy radiation therapy (RT) (standard dose) vs 74-Gy RT (high dose) with concurrent and consolidation chemotherapy with or without cetuximab. This study asked whether or not RT dose escalation (and/or cetuximab) improved overall survival. The sobering answer was no: the survival rate was lower in the high-dose RT arm, and the addition of cetuximab made no difference.¹